• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » HHS Report Criticizes FDA’s Human Subject Protection Efforts and Lack of Site Audits

HHS Report Criticizes FDA’s Human Subject Protection Efforts and Lack of Site Audits

September 28, 2007
CenterWatch Staff

The U.S. Food and Drug Administration (FDA) audited fewer than 1% of investigative sites, the inspector general of the Department of Health and Human Services (HHS), Daniel R. Levinson, found in a report released Friday.

The 41-page report said the FDA has just 200 specially-trained inspectors to audit an estimated 350,000 investigative sites. Others estimate that the number of sites is much lower.

The report found that federal health officials did not even know how many clinical trials were being conducted in the U.S. According to CenterWatch, an estimated 59,000 drug trials, phases I, II and III, were being conducted worldwide in 2006.

The Office of Inspector General (OIG) investigated after receiving a congressional request to review FDA’s oversight of clinical trials  a series of news articles highlighted vulnerabilities, the OIG report said. “The series identified problems with FDA’s oversight of clinical trials, including insufficient informed consent procedures, inadequate training and certification requirements for IRBs, limited Federal regulations, and FDA’s failure to enforce existing regulations,” the OIG report added.

The report said FDA “views its protocol review before a clinical trial commences as the most important step in protecting human subjects. We recognize the important role that FDA’s protocol review plays in protecting human subjects and made several changes to our report to reflect this point. We do note, however, that this report addresses another important part of the system for protecting human subjects: oversight of the trials once they are actually underway.”

Levinson’s report said that when those overburdened inspectors found serious problems in clinical trials, their superiors in Washington downgraded their findings 68% of the time. And the report found that in the remaining cases, the FDA almost never followed up with inspections to determine whether the corrective actions that the agency specified had been done.

“The report issued today by the Department of Health and Human Services Office of Inspector General offers valuable insight into FDA’s program to protect clinical trial participants. The agency agrees with the report and is already acting on all its recommendations. Volunteers play a critical role in making treatments available that help millions of patients and FDA is committed to ensuring strong oversight to protect participants,” said Heidi Rebello, spokesperson for Office of the Commissioner at the FDA.

As its mission has grown, FDA has been widely criticized as underfunded in numerous areas beyond clinical trials, such as drug importation and food safety.

The HHS’ inspector general found the FDA disqualified investigators from conducting clinical trials 26 times from 2000 to 2005 and disqualified their data only twice even though the agency found serious problems at trial sites 348 times during that period.

The inspector general also recommended that the agency create a registry of continuing clinical trials, launch a registry of research ethics boards, build a database to track its research inspections and get more authority to regulate research assistants.

OIG identified five steps that could take to improve its system of oversight:

  • Develop a comprehensive internal database of all clinical trials,
  • Create a registry of IRBs,
  • Create a cross-center database that allows complete tracking of FDA inspections,
  • Seek legal authority to provide oversight that reflects current clinical trial practices; and
  • Establish a mechanism to provide feedback to FDA district office staff on their inspection reports and findings.

Read the OIG report here.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing